UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 162

Sortiert nach

A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis

Clinical gastroenterology and hepatology, 2017-12, Vol.15 (12), p.1940-1949.e8

2017

Link zum Volltext

Verfügbarkeit prüfen

Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease

Journal of gastroenterology and hepatology, 2014-07, Vol.29 (7), p.1470-1476

2014

Link zum Volltext

Verfügbarkeit prüfen

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Hepatology international, 2020-12, Vol.14 (6), p.889-919

2020

Link zum Volltext

Verfügbarkeit prüfen

Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment

Journal of gastroenterology and hepatology, 2018-01, Vol.33 (1), p.70-85

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparison between obese and non-obese nonalcoholic fatty liver disease

Clinical and molecular hepatology, 2023-02, Vol.29 (Suppl), p.S58-S67

Chan, Wah-Kheong

2023

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus

Digestive diseases and sciences, 2020-02, Vol.65 (2), p.623-631

2020

Link zum Volltext

Verfügbarkeit prüfen

Metabolic fatty liver syndromes: where do we stand in 2024?

Journal of gastroenterology and hepatology, 2024-04, Vol.39 (4), p.613-614

2024

Link zum Volltext

Verfügbarkeit prüfen

Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography

Journal of gastroenterology and hepatology, 2019-08, Vol.34 (8), p.1396-1403

2019

Link zum Volltext

Verfügbarkeit prüfen

Epidemiology of Helicobacter pylori Infection and Public Health Implications

Helicobacter (Cambridge, Mass.), 2011-09, Vol.16 (s1), p.1-9

2011

Link zum Volltext

Verfügbarkeit prüfen

Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B

Journal of viral hepatitis, 2020-12, Vol.27 (12), p.1297-1305

2020

Link zum Volltext

Verfügbarkeit prüfen

Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B

Journal of viral hepatitis, 2023-08, Vol.30 (8), p.712-712

2023

Link zum Volltext

Verfügbarkeit prüfen

Meaning of non‐overlapping patients between the MAFLD and NAFLD definitions

Liver international, 2022-02, Vol.42 (2), p.271-273

2022

Link zum Volltext

Verfügbarkeit prüfen

The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups

Journal of gastroenterology and hepatology, 2018-01, Vol.33 (1), p.86-98

2018

Link zum Volltext

Verfügbarkeit prüfen

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease

Journal of gastroenterology and hepatology, 2022-05, Vol.37 (5), p.795-811

2022

Link zum Volltext

Verfügbarkeit prüfen

MACK‐3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non‐alcoholic steatohepatitis

Liver international, 2019-07, Vol.39 (7), p.1315-1324

2019

Link zum Volltext

Verfügbarkeit prüfen

Can the same controlled attenuation parameter cut‐offs be used for M and XL probes for diagnosing hepatic steatosis?

Journal of gastroenterology and hepatology, 2018-10, Vol.33 (10), p.1787-1794

2018

Link zum Volltext

Verfügbarkeit prüfen

Is metabolic‐dysfunction‐associated fatty liver disease or advanced liver fibrosis associated with erythropoietin stimulating agent hypo‐responsiveness among patients with end‐stage kidney disease on haemodialysis?

Nephrology (Carlton, Vic.), 2023-08, Vol.28 (8), p.425-433

2023

Link zum Volltext

Verfügbarkeit prüfen

Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease

Liver international, 2020-11, Vol.40 (11), p.2719-2731

2020

Link zum Volltext

Verfügbarkeit prüfen

Liver stiffness measurement in non‐alcoholic fatty liver disease: Two is better than one

Journal of gastroenterology and hepatology, 2020-08, Vol.35 (8), p.1404-1411

2020

Link zum Volltext

Verfügbarkeit prüfen

Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus

Journal of gastroenterology and hepatology, 2021-03, Vol.36 (3), p.751-757

2021

Link zum Volltext

Verfügbarkeit prüfen

Development and validation of a novel non‐invasive test for diagnosing fibrotic non‐alcoholic steatohepatitis in patients with biopsy‐proven non‐alcoholic fatty liver disease

Journal of gastroenterology and hepatology, 2020-10, Vol.35 (10), p.1804-1812

2020

Link zum Volltext

Verfügbarkeit prüfen

Reply to: CHAI and MACK‐3 as noninvasive indices for nonalcoholic steatohepatitis

Liver international, 2019-08, Vol.39 (8), p.1588-1588

2019

Link zum Volltext

Verfügbarkeit prüfen

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Clinical and molecular hepatology, 2023-04, Vol.29 (2), p.401-403

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 162

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAlimentary Pharmacology & Therapeutics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(152)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(109)
Life Sciences & Biomedicine
(104)
Gastroenterology & Hepatology
(90)
Humans
(69)
Liver Diseases
(43)
Fatty Liver
(41)
Female
(34)
Male
(34)
Middle Aged
(33)
Biopsy
(30)
Fibrosis
(28)
Hepatology
(25)
Nafld
(23)
Non-Alcoholic Fatty Liver Disease
(23)
Adult
(19)
Gastroenterology
(19)
Liver
(19)
Non-Alcoholic Fatty Liver Disease - Diagnosis
(19)
Patients
(18)
Steatosis
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis

Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment

Comparison between obese and non-obese nonalcoholic fatty liver disease

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus

Metabolic fatty liver syndromes: where do we stand in 2024?

Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography

Epidemiology of Helicobacter pylori Infection and Public Health Implications

Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B

Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B

Individual Patient Data Meta-Analysis of Controlled Attenuation Parameter (CAP) Technology for Assessing Steatosis

Meaning of non‐overlapping patients between the MAFLD and NAFLD definitions

The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease

MACK‐3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non‐alcoholic steatohepatitis

Can the same controlled attenuation parameter cut‐offs be used for M and XL probes for diagnosing hepatic steatosis?

Is metabolic‐dysfunction‐associated fatty liver disease or advanced liver fibrosis associated with erythropoietin stimulating agent hypo‐responsiveness among patients with end‐stage kidney disease on haemodialysis?

Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease

Liver stiffness measurement in non‐alcoholic fatty liver disease: Two is better than one

Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus

Development and validation of a novel non‐invasive test for diagnosing fibrotic non‐alcoholic steatohepatitis in patients with biopsy‐proven non‐alcoholic fatty liver disease

Reply to: CHAI and MACK‐3 as noninvasive indices for nonalcoholic steatohepatitis

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Aktive Filter

Suchergebnisse filtern